DSTF Summer meeting: Early clinical research in Denmark
As we have a limited number of seats, please send an email to Charlotte: (ckhs@novonordisk.com) no later than 11 June 2024, for registration. Your registration will be confirmed by email.
Programme
11.00-11.10: Welcome. Anders Jensen, Professor; Copenhagen University, Chair; Danish Society for
Toxicology and Pharmacology.
11.10-11.30: Denmark as the preferred country for early clinical trials. Kirsten Bødker, Head of
Business Relations; Trial Nation.
11.30-12.15: The regulatory landscape for early phase research from the Danish authorities’
perspective. Lene Grejs Petersen, Senior Adviser, Clinical Trials; Danish Medicines Agency &
Helle Christiansen, Special Adviser; Danish National Center for Ethics.
12.15-13.00: Lunch
13.00-13.20: First-in-human oncology trials - comprehensive genomic profiling for identifying and
treating patients. Martin Højgaard, Clinical Oncologist, Phase 1 Unit; Rigshospitalet.
13.20-13.40: Establishing the Novo Nordisk Clinical Innovation Centre (CLINiC). Camilla Wamberg,
Senior Director, CLINiC; Novo Nordisk A/S & Melissa Voigt Bolten Jagd; Scientific Medical
Director, CLINiC; Novo Nordisk A/S.
13.40-14.00: Strengths/challenges for trials in DK – 2 case studies. Kim Kjøller, CEO; Union
Therapeutics.
14.00-14.20: Advancing diabetes care: Clinical insights from Steno Diabetes Center Aarhus.
Professor Søren Gregersen, Medical Lead, Trial Unit; Steno Diabetes Center Aarhus.
14.20-14.50: Nonclinical development and phase 1 of cell therapies: a Parkinsons Disease case.
Frederikke Lihme Egerod, Non-Clinical Project Director; Novo Nordisk A/S.
14.50-15.20: Coffee
15.20-15.40: Sanos Group - Phase 1 and Beyond; Bernt Husøy, Chief Physician; Sanos Clinic & Casper
Clemmensen, Chief Commercial Officer; Sanos Group.
15.40-16.00: A phase 0 observational study supporting clinical development of ClC-1 inhibitors for
the treatment of Charcot-Marie-Tooth disease – an NMD Pharma/AUH case. Thomas
Grønnebæk, Clinical scientist; NMD Pharma.
16.00-16.30: Zelo phase I unit and DanTrials - a joint venture at Bispebjerg Hospital. David Peick
Sonne, Head of Zelo Phase I Unit & Torben Balchen, CEO; DanTrials.
16.30-16.50: Patient perspective on early clinical trials. Speaker to be announced.
16.50-17.00: Wrap-up
